Industry must step up to tackle AMR threat

Generics manufacturers must “step up” to tackle antimicrobial resistance (AMR), the Access to Medicine Foundation has insisted, in a report that “systematically evaluates how a cross-section of the pharmaceutical industry is responding to the AMR threat”.

Generics manufacturers must “step up” to tackle antimicrobial resistance (AMR), the Access to Medicine Foundation has insisted, in a report that “systematically evaluates how a cross-section of the pharmaceutical industry is responding to the AMR threat”.

Entitled ‘Antimicrobial Resistance Benchmark 2018’, the report compares 30 companies, including 10 generic medicine manufacturers, eight large research-based pharmaceutical companies...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Archive

More from Generics Bulletin